Welcome to our dedicated page for Cullinan Oncology SEC filings (Ticker: CGEM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cullinan Therapeutics, Inc. (Nasdaq: CGEM) SEC filings page on Stock Titan provides access to the company’s public disclosures filed with the U.S. Securities and Exchange Commission. These documents include Current Reports on Form 8-K, which Cullinan uses to report material events such as clinical data updates, financial results, regulatory milestones, and significant corporate actions related to its biopharmaceutical business.
For a clinical-stage company like Cullinan, SEC filings are a primary source of detail on the development of its T cell engager and targeted therapy programs. Recent 8-K filings describe updated Phase 1 data for CLN-049, an FLT3xCD3 bispecific T cell engager in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome, including response rates, safety findings, and the impact of FDA Fast Track designation. Other filings summarize financial results, cash and investment levels, and expectations for cash runway under the company’s operating plan.
Filings may also reference Cullinan’s work in autoimmune diseases with CLN-978, a CD19xCD3 bispecific T cell engager, and its collaboration with Taiho Oncology and Taiho Pharmaceutical on zipalertinib (CLN-081/TAS6417), an EGFR inhibitor for non-small cell lung cancer. These reports can include information on clinical timelines, regulatory interactions, and program prioritization decisions, such as the discontinuation of certain assets or the termination of license agreements.
On Stock Titan, investors can review Cullinan’s SEC filings alongside AI-powered summaries that highlight key points from lengthy documents, helping to interpret complex clinical and regulatory language. Users can monitor new 8-K submissions in real time and place them in context with the company’s broader pipeline and news flow, supporting deeper analysis of CGEM’s risk profile, development progress, and strategic direction.
Cullinan Therapeutics, Inc. Chief Legal Officer Jacquelyn L. Sumer reported an open-market sale of 3,601 shares of common stock at $14.47 per share on February 24, 2026. According to the footnote, the sale was made to cover personal income tax obligations upon vesting of restricted stock units. After this transaction, she directly owned 128,089 shares.
Jennifer Michaelson reported multiple 10b5-1 sales of common stock under Form 144, covering transactions from 12/12/2025 through 02/23/2026. The filing lists several dispositions, including 8,000 shares on 02/20/2026 and 1,752 shares on 02/23/2026.
Cullinan Therapeutics Chief Medical Officer trades shares to cover taxes. Jeffrey Alan Jones reported an open-market sale of 4,982 shares of common stock at $13.62 per share on February 20, 2026, to cover personal income tax obligations upon vesting of restricted stock units, and now holds 164,550 shares directly.
Cullinan Therapeutics, Inc. Chief Scientific Officer Jennifer Michaelson reported multiple equity transactions in company stock. On February 20, 2026, she exercised stock options for 8,000 shares of common stock at a stated exercise price of $4.30 per share, reflected through derivative and non-derivative entries. She then sold a total of 11,742 shares of common stock in open-market transactions at prices of $13.62 and $14.30 per share. A footnote states that a portion of the sales was made to cover personal income tax obligations upon vesting of restricted stock units and that the transactions were effected under a Rule 10b5-1 trading plan established on August 7, 2025. Following these transactions, her reported direct ownership remained in the range of approximately 180,000–190,000 shares of Cullinan Therapeutics common stock.
Cullinan Therapeutics Chief Legal Officer sells shares for taxes. Jacquelyn L. Sumer executed an open-market sale of 3,742 shares of Cullinan Therapeutics common stock at $13.62 per share on February 20, 2026 to cover personal income tax obligations upon vesting of restricted stock units. After this transaction, she directly holds 131,690 shares.
Cullinan Therapeutics, Inc. President and CEO Nadim Ahmed reported an open-market sale of common stock. On February 20, 2026, he sold 16,381 shares at an average price of $13.62 per share, according to the Form 4 filing.
A footnote explains the sale was made to cover personal income tax obligations arising from the vesting of restricted stock units. After this transaction, Ahmed still holds 404,318 shares of Cullinan Therapeutics common stock directly.
Cullinan Therapeutics Chief Financial Officer Mary Kay Fenton reported a tax-related share sale. On this Form 4, she sold 4,398 shares of common stock at $13.62 per share in an open-market transaction. According to the footnote, the sale was made to cover personal income tax obligations upon vesting of restricted stock units. After this transaction, she directly owned 126,380 shares of Cullinan Therapeutics common stock.
CGEM filing shows a proposed resale of 1,752 shares of common stock through Morgan Stanley Smith Barney LLC.
The filing lists multiple recent 10b5-1 sales by Jennifer Michaelson, including 8,000 shares sold on 02/20/2026 for $114,400.00 and 4,000 shares sold on 01/22/2026 for $49,200.00.
Jennifer Michaelson proposes sale of 8,000 common shares. The filing lists 8,000 shares to be sold on 02/20/2026 via an exercise of stock options with cash consideration. The record also lists prior 10b5-1 sales totaling multiple transactions in 2025–2026.
Cullinan Therapeutics, Inc. reported that Chief Legal Officer Jacquelyn L. Sumer received a grant of a stock option covering 230,000 shares of common stock. This option was reported as an acquisition of a derivative security.
According to the disclosure, the shares underlying the option vest over four years, with one forty-eighth of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. Following this grant, Sumer was reported as directly holding options on 230,000 shares.